• LAST PRICE
    21.4800
  • TODAY'S CHANGE (%)
    Trending Down-0.3500 (-1.6033%)
  • Bid / Lots
    21.4000/ 1
  • Ask / Lots
    21.6500/ 2
  • Open / Previous Close
    21.9600 / 21.8300
  • Day Range
    Low 21.4800
    High 22.2100
  • 52 Week Range
    Low 3.7800
    High 22.2100
  • Volume
    21,977
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 21.83
TimeVolumePLSE
09:32 ET832121.7
09:34 ET67521.9654
09:36 ET200021.8867
09:38 ET173821.6
09:41 ET21121.81
09:43 ET222821.9
09:45 ET240121.815
09:48 ET127521.6579
09:50 ET70021.48
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPLSE
Pulse Biosciences Inc
1.3B
-27.1x
---
United StatesNNOX
Nano-X Imaging Ltd
447.5M
-7.4x
---
United StatesSLP
Simulations Plus Inc
749.5M
78.9x
+3.18%
United StatesATLN
Atlantic International Corp
290.4M
-0.6x
---
United StatesOBIO
Orchestra Biomed Holdings Inc
241.3M
-4.2x
---
United StatesMXCT
MaxCyte Inc
446.6M
-12.4x
---
As of 2024-08-22

Company Information

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Contact Information

Headquarters
3957 Point Eden WayHAYWARD, CA, United States 94545-3720
Phone
510-906-4600
Fax
302-655-5049

Executives

Executive Co-Chairman of the Board
Robert Duggan
Independent Co-Chairman of the Board
Paul Laviolette
President, Chief Executive Officer, Director
Burke Barrett
Chief Technology Officer, Director
Darrin Uecker
Chief Commercial Officer
Kevin Danahy

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$0.00
Shares Outstanding
61.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.76
EPS
$-0.79
Book Value
$0.80
P/E Ratio
-27.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.